1683POne-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan

ConclusionsThese interim results suggest that ERI may be an option for patients with various types of STS, including non-L-type sarcomas.Legal entity responsible for the studyEisai Co., Ltd.FundingEisai Co., Ltd.DisclosureS. Takahashi: Advisory / Consultancy: Eisai Co., Ltd. Y. Megumi: Full / Part-time employment: Eisai Co., Ltd. Y. Sakata: Full / Part-time employment: Eisai Co., Ltd. H. Ikezawa: Full / Part-time employment: Eisai Co., Ltd. T. Matsuoka: Full / Part-time employment: Eisai Co., Ltd. A. Kawai: Advisory / Consultancy: Eisai Co., Ltd.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research